Cd5 Specific T Cell Receptor Cell or Gene Therapy

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent relates to a new form of immunotherapy targeting T-cell cancers such as T-cell lymphoma and T-cell leukemia. The invention provides engineered T cell receptors (TCRs) that specifically recognize the CD5 antigen, a marker commonly found on malignant T-cells, when presented by certain human MHC molecules (specifically HLA-A*02). These TCRs can be introduced into patient or donor T cells for adoptive cell therapy or gene therapy. The patent also addresses technical challenges such as preventing the engineered T-cells from attacking each other (fratricide), by using gene-editing or RNAi to suppress key proteins (CD5 or HLA-A*02) in the therapeutic cells.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of patients with CD5-positive T-cell lymphomas or leukemias, especially those refractory to standard therapies.
• Adoptive cell transfer therapy using engineered T-cells in cancer treatment centers.
• Use as a second-line or salvage therapy for relapsed or otherwise treatment-resistant T-cell cancers.
• Potential use in combination with allogeneic stem cell transplants for advanced hematologic malignancies.
• Development of diagnostic kits for detection or monitoring of CD5 antigen-presenting tumor cells.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets a critical unmet medical need in treating aggressive T-cell cancers that are resistant to chemotherapy.
• Engineered TCRs provide high specificity for malignant cells, sparing healthy tissues and reducing side effects.
• Innovative strategies (such as RNAi or gene-editing) prevent therapeutic T-cells from attacking themselves, improving cell viability and efficacy.
• Customizable for use in different transplantation settings (autologous, allogeneic, HLA-mismatched or haploidentical), broadening patient eligibility.
• Potentially improves overall survival and remission rates in patients with poor prognosis T-cell malignancies.
• Can be manufactured as gene therapy products, kits, or pharmaceutical compositions, facilitating clinical deployment.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a peptide from the T-cell lineage specific antigen CD5, preferably SEQ ID NO: 1, in the context of a human MHC I such as HLA-A*02, in particular HLA-A*02:01. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, expressing said TCR construct. Treatment optionally is in the context of allogeneic stem cell transplantation, in particular, mismatch-transplantation, or haploidentical transplantation, or in combination with an agent capable of inhibiting expression of HLA-A*02 in the TCR-transgenic T cells. The invention thus also provides compositions and kits comprising the nucleic acids of the invention in combination with an agent capable of inhibiting expression of HLA-A*02, and, as well as the medical use of such compositions and kits. The nucleic acids, compositions and kits, proteins or host cells may be for use in the diagnosis, prevention and/or treatment of a CD5-positive T-cell lymphoma or T-cell leukemia, no matter whether the antigen is expressed on the cell surface, intracytoplasmic or in both manners.